

Dose Individualization for Cancer Chemotherapy

Gary Rosner

Department of Biostatistics

U.T. M.D. Anderson Cancer Ctr

PODE Workshop

June 2009

The Motivating Problem

- Dr. Borje Andersson @ MDACC
 - Ultra high-dose therapy to treat leukemia
 - Dose too high?
 - Fatal toxicity
 - Dose too low?
 - Less chance for benefit
 - Solution
 - Choose “optimal” dose

Bayesian Modeling

- **Incorporates prior info**
 - Previous studies
 - “Expert” opinion
- **Predict & estimate precision**
 - Based on current knowledge
 - Can incorporate information from outside of current study

Optimal Individualized Dose

- Jelliffe et al.
- D'Argenio & Rodman
- Wakefield
 - Constant & quadratic loss functions
- Sandstrom, Karlsson, Ljungman, et al.
 - Individualization of oral busulfan

Back to Transplant Study

- **Have previous studies**
 - 1/day dosing & 2/day dosing
- **Current study**
 - 12 mg i.v. test dose
 - Uniform high dose (mg/m²)
- **Future study**
 - Test dose ⇒ PK ⇒ “Optimal”

What We Would Like To Do

- **Combine**
 - Meta-analysis of PK from earlier studies
 - PK of test dose for new patient
- **Predict PK for new patient**
 - Determine optimal dose
 - Bayesian Decision Theory

Data

Study	Pt. #	Dose	Time	Conc	Covar
1	1	HIGH	$t_{1,1,1}, \dots$	$y_{1,1,1}, \dots$	$x_{1,1}, \dots$
...
1	i	HIGH	$t_{1,i,j}, \dots$	$y_{1,i,j}, \dots$	$x_{1,i}, \dots$
...
1	n_1	HIGH	$t_{1,n_1,j}, \dots$	$y_{1,n_1,1}, \dots$	x_{1n_1}, \dots
2	1	low	$t_{2,1,1}, \dots$	$y^*_{2,1,1}, \dots$	$x_{2,1}, \dots$
2	1	HIGH	$t_{2,1,1}, \dots$	$y_{2,1,1}, \dots$	$x_{2,1}, \dots$
...
2	i	low	$t_{2,i,1}, \dots$	$y^*_{2,i,1}, \dots$	$x_{2,i}, \dots$
2	i	HIGH	$t_{2,i,1}, \dots$	$y_{2,i,1}, \dots$	$x_{2,i}, \dots$
...
2	n_2	low	$t_{2,n_2,1}, \dots$	$y^*_{2,n_2,1}, \dots$	x_{2,i,n_2}, \dots
2	n_2	HIGH	$t_{2,n_2,1}, \dots$	$y_{2,n_2,j}, \dots$	x_{2,n_2}, \dots
3	1	low	$t_{3,1,1}, \dots$	$y^*_{3,1,1}, \dots$	$x_{3,1}, \dots$

Sampling Distribution Nonlinear Mean Function

- For pt. i , in study s , at time t_{sij}

$$\begin{aligned}y_{s,i,j} &= \log [\text{Conc}(t_{s,i,j})] \\&= \log [f(t_{s,i,j})] + error\end{aligned}$$

Population Model as Hierarchical Model

- **Observation**

$$p(y_{s,i,j} \mid \theta_i), s = 1, \dots, S; j = 1, \dots, n_i$$

- **Subject-specific parameters**

$$p(\theta_i \mid \phi), i = 1, \dots, I$$

- **Population**

$$p(\phi)$$

Mixture Models for Population Distribution

- **Distribution of subject-specific parameters:**

$$p(\theta_i \mid \phi), i = 1, \dots, I$$


- **Characterize as a mixture of simpler distributions**

- **Weighted sum of densities**

$$\begin{aligned} p(\theta_i \mid \phi) &= \text{Mixture of MV Normals} \\ &= \sum_k w_k N(\mu_k, V) \end{aligned}$$

Why Mixture?

- **Flexible: Depict Many Shapes**
 - **Heterogeneity:**
 - patient characteristics
 - genetic diversity
- **Example:**
 - **Mixtures of normal densities (kernels)**



Dirichlet Process (DP)

Mixture of Normals

- Dirichlet Process is distribution on space of distributions
- DP has 2 parameters
- G_0 is base measure
- M is total mass parameter

$$\mu_i \sim G$$

$$G \sim DP(G_0, M) \quad i.e., G = \sum_{h=1}^{\infty} w_h \delta(\mu_h)$$

$$G_0(\mu) = N(b, B)$$

Hierarchical Model: Within Study

$$\log(y_{ij}) = \log[f(\theta_i, t_{ij})] + \varepsilon_{ij}$$





$$\varepsilon_{ij} \sim N(0, \tau^{-1}), \quad \tau \sim Ga(\alpha_\tau, \beta_\tau)$$

$$\left. \begin{array}{l} \theta_i \sim N(\mu_i, S) \\ \mu_i \sim G \end{array} \right\} \Rightarrow \theta_i \sim \sum_{h=1}^{\infty} w_h N(\mu_h, S)$$

$$G \sim DP(G_0, m) \quad i.e., G = \sum_{h=1}^{\infty} w_h \delta(\mu_h)$$

Multiple Studies Hyperprior for Meta-Analysis

- **Straightforward if parametric hyperprior (random effects)**
 - Parametric model provides structure
- **Complex if mixture hyperprior**
 - Link studies at what level?
 - How enforce linkage?



How Model Commonality?

Want to Share More Info From Prior Studies

- **Dependent Dirichlet Process**
 - ANOVA-like structure for means
 - Categorical covariates: $x = (v, w)$
 - Locations linked across factor levels of x via ANOVA model

$$G_x(\phi) = \sum w_h \delta(m_{xh}),$$

$$m_{xh} = \mu_h + A_{v,h} + B_{w,h}$$

Dependence Structure

DP Mixture of ANOVA (categorical)

- **Across levels of x (C levels)**

$$x = x_1, x_2, \dots, x_C$$

$$x = x_1 : G_{x_1} = \omega_1 \delta(m_{11}) + \omega_2 \delta(m_{12}) + \omega_3 \delta(m_{13}) + \dots$$

$$x = x_2 : G_{x_2} = \omega_1 \delta(m_{21}) + \omega_2 \delta(m_{22}) + \omega_3 \delta(m_{23}) + \dots$$


$$x = x_3 : G_{x_3} = \omega_1 \delta(m_{31}) + \omega_2 \delta(m_{32}) + \omega_3 \delta(m_{33}) + \dots$$

...





- **Locations are functions of x**

$$m_{xh} = \mu_h + A_{v,h} + B_{w,h}$$

2 Factors, 2 Levels Each:



Compare Mixture to ML Estimation



Covariates

- **Dependent Dirichlet Process (DDP)**
 - Decompose locations as sums of random measures
- **Categorical covariates**
 - ANOVA DDP
 - Two factors v and w : $x = (v, w)$
 $m_{xh} = \mu_h + A_{v,h} + B_{w,h}$
- **Categorical & continuous covariates**
 - Linear DDP
 - One categorical & 1 continuous $x = (v, z)$
 $m_{xh} = \mu_h + A_{vh} + \beta_h z$

Back to Transplant Study


- **Multiple studies**
 - **Hierarchical extension**
 - **G is 2x3 matrix-variate dist'n**

$$\theta_{ki} \sim \int N(\mu_{ki}, S) dG_{ki}(\mu_{ki}), k = 1, 2, 3$$




$$A \sim G$$

$$A = [m, ST_2, ST_3] = \begin{pmatrix} \text{Main} & \text{Study2} & \text{Study3} \\ \log V_0 & \log V_2 & \log V_3 \\ \log k_0 & \log k_2 & \log k_3 \end{pmatrix}$$

Have 2 Studies



Fitted Profiles




Incorporate
Test Dose

Back to Transplant Example


- **Have**
 - Model for drug's PK
 - Probability model for data
- **Need utility function to optimize**

Dose Optimization



Too Low

AUC too low!



Too High

AUC too high!

TARGET

Bayesian Optimal Design

- **Let** $u(y,d,\theta) = L(AUC)$, $AUC = f(d,V,k)$

- **Pick dose d^* that minimizes**


$$E[u(y,d,\theta)] = \iint u(y,d,\theta) p_d(y,\theta) dy d\theta$$

- **With data:**
 - Studies 1 & 2 plus new patient's low dose data

$$E[u(y,d,\theta)] = \int L[AUC(\theta,d)] p(\theta|D) d\theta$$

Asymmetric Loss Function

- Want AUC in “optimal” range




- Loss function

$$L(auc) = \begin{cases} L^-(auc, AUC_{ll}) & \text{if } auc < AUC_{ll} \\ 0 & \text{if } AUC_{ll} < auc < AUC_{ul} \\ L^+(auc, AUC_{ul}) & \text{if } auc > AUC_{ul} \end{cases}$$


For Study 3: Posterior for this patient's PK parameters

Third Study




Optimal Dose w.r.t. Posterior

Loss Function



Expected Loss



Summary

- Mixture models
 - flexible inference
- DDP structure
 - Categorical and continuous covariates
- Optimal design for PK
- Currently evaluating our strategy against covariate-based dosing

Спасибо